Metronidazole Fresenius (Metronidazole)

Metronidazole is taken up by anaerobic microorganisms and reduced to reactive nitro radical anions. These radicals damage DNA by causing strand breaks and loss of helical stability, which blocks nucleic acid synthesis and leads to cell death, providing selective activity against anaerobes and some protozoa.

The dosing regimen for Metronidazole Fresenius is determined by the prescribing clinician based on the infection type, severity, patient weight, and renal or hepatic function. Typical intravenous courses range from 500 mg to 1 g every 8 hours, but exact dosing must follow the prescriber’s order.

Metronidazole is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy only if the potential benefit justifies any potential risk. Limited data suggest it is compatible with breastfeeding, but clinical judgment is required.

To order Metronidazole Fresenius, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. The sales team then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

The primary alternative to metronidazole for anaerobic infections is clindamycin. Both agents cover similar anaerobic bacteria, but metronidazole has superior activity against certain protozoa (e.g., Trichomonas, Entamoeba) and a lower risk of Clostridioides difficile infection. Clindamycin may be preferred when metronidazole intolerance occurs, but it carries a higher incidence of gastrointestinal side effects.

Metronidazole Fresenius should be stored refrigerated at 2 °C to 8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If a temporary temperature excursion occurs, discard the product if visual changes are observed.

Metronidazole Fresenius is given by intravenous infusion. The solution is typically diluted in compatible IV fluids (e.g., 5% dextrose or normal saline) and infused over 30–60 minutes, depending on the prescribed dose and clinical setting. Administration should follow aseptic technique and institutional infusion protocols.

Serious adverse events associated with metronidazole include seizures, peripheral neuropathy (which may be irreversible), severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, neutropenia, and hepatic dysfunction. Patients should be monitored for neurological symptoms, skin reactions, and liver function abnormalities during therapy.

Metronidazole Fresenius should be avoided in individuals with a known hypersensitivity to metronidazole or other nitroimidazoles, in patients with severe hepatic impairment, and in those who are currently consuming alcohol due to the risk of a disulfiram‑like reaction. Caution is also advised for patients with significant renal dysfunction.